Phase I trial of temozolomide (CCRG 81045: M&U 39831: NSC 362856)

British Journal of Cancer

Volumn 65, Issue 2, 1992, Pages 287-291

  Newlands, E S ^a   Blackledge, G R P ^b   Slack, J A ^c   Rustin, G J S ^a,d   Smith, D B ^a   Stuart, N S A ^b   Quarterman, C P ^c   Hoffman, R ^a   Stevens, M F G ^c   Brampton, M H ^a   Gibson, A C ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c ASTON UNIVERSITY   (United Kingdom)

^d MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; TEMOZOLOMIDE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER REGRESSION; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SCREENING; FEMALE; GLIOMA; HUMAN; LEUKOPENIA; MALE; MELANOMA; MYCOSIS FUNGOIDES; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; DACARBAZINE; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; FEMALE; GLIOMA; HUMAN; KIDNEY NEOPLASMS; MALE; MELANOMA; MIDDLE AGE; NEOPLASMS; STOMACH NEOPLASMS;

EID: 0026513077     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1992.57     Document Type: Article

References (18)

1. BLACKLEDGE, G., ROBERTS, J.T., KAYE, S B. & 4 others (1989). Phase II study of mitozolomide in metastatic transitional cell carcinoma of the bladder. Eur. J. Cancer Clin. Oncol., 25, 391.
2. BRINDLEY, C.J., ANTONIW, P. & NEWLANDS, E.S. (1986). Plasma and tissue disposition of mitozolomide in mice. Br. J. Cancer, 53, 91.
3. BULL, V.L. & TISDALE, M.J. (1987). Antitumour imidazotetrazines XVI. Macromolecular alkylation by 3-substituted imidazotetrazines. Biochem. Pharmacol., 36, 3215.
4. GIBSON, N.W., HARTLEY, J.A., MATTES, W.B., KOHN, K.W. & ERICKSON, L.D. (1985). The effects of pretreatment of human tumour cells with MNNG on the DNA crosslinking and cytotoxicity of two chloroethylating agents. Abstract: International Conference on Mechanisms of DNA Damage and Repair. Implications for Carcinogenesis and Risk Assessment. Gaithersburg: Maryland. June 2-7.
5. GIBSON, N.W., HICKMAN, J.A. & ERICKSON, L.D. (1984). Effects of the antitumour agent 8-carbamoyl-3-(2-chloroethyl)imidazo[5, l-d]l,2,3,5-tetrazin-4(3H)-one on the DNA of mouse L1210 cells. Cancer Res., 44, 1767.
6. GIBSON, N.W., HICKMAN, J.A. & ERICKSON, L.D. (1985). DNA crosslinking and cytotoxicity in normal and transferred human cells treated in vitro with 8-carbamoyl-3-(2-chloroethyl)-imidazo [5-l-d], l,2,3,5-tetrazin-4(3H)-one. Cancer Res., 44, 1772.
7. GUNDERSON, S., A AM DAL, S. & FODSTAD, O. (1987). Mitozolomide (NSC35451), a new active drug in the treatment of malignant melanoma. Phase II trial in patients with advanced disease. Br. J. Cancer, 55, 433.
8. HARDING, M., NORTHCOTT, D., SMYTH, J., STUART, N.S.A., GREEN, J.A. & NEWLANDS, E.S. (1988). Short communication in: Phase II evaluation of mitozolomide in ovarian cancer. Br. J. Cancer, 57, 113.
9. HARTLEY, J.A., GIBSON, N.W., KOHN, K.W. & MATTES, W.B. (1986). DNA sequence selectivity of guanine-N7 alkylation by three antitumour chloroethylating agents. Cancer Res., 46, 1943.
10. HERIAT, P., ROUGIER, P., OLIVEIRA, J. & 4 others (1988). Phase II study of mitozolomide (M&B39565) in colorectal and breast cancer. Invest. New Drugs, 6, 323.
11. NEIJT, J.P., VAN DER BURG, M.E., GUASTALLA, J.P., GEORGE, M., VERMORKEN, J.B. & ROTMENTSZ, N. (1987). Mitozolomide in patients with advanced ovarian carcinoma: a Phase II study of the EORTC Gynaecological Cancer Cooperative Group. Abstract: Proc., ECCO-4. Fourth European Cancer Conference on Clinical Oncology and Cancer Nursing; Federation of European Cancer Studies, Madrid, p. 214. Nov 1-7.
12. NEWLANDS, E.S., BLACKLEDGE, G., SLACK, J.A. & 4 others (1985). Phase I clinical trial of mitozolomide. Cancer Treatment Reports, 69, 7-8 July/Aug.
13. SCHORNAGEL, J.H., SIMONETTI, G. & McVIE, J.G. (1986). Phase I study of mitozolomide (NSC 54351) using a daily x 5 schedule. Proc. Fifth NCI-EORTC Symposium on New Drugs in Cancer Therapy. Abstract.
14. SLACK, J.A. & GODDARD, C. (1985). Antitumour imidazotetrazines VII. Quantitative analysis of mitozolomide in biological fluids by HPLC. J. Chromatogr., 337, 178.
15. STEVENS, M.F.G., HICKMAN, J.A., LANGDON, S.P. & 11 others (1987). Antitumour activity and pharmacokinetics in mice of 8-carbamoyl-3-methylimidazo [5,1-d] 1, 2, 3, 5-tetrazin-4 (3H) one (CCRG) 81045; M&B (39831) a novel drug with potential as an alternative to dacarbazine. Cancer Res., 41, 5846.
16. STEVENS, M.F.G., HICKMAN, J.A., STONE, R. & 4 others (1984). Antitumour imidazotetrazines 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl) imidazo [5, 1, d] -1, 2, 3, 5-tetrazin-4(3H)-one, a novel broad spectrum antitumour agent. J. Med. Chem., 27, 196.
17. TSANG, L.L.H., QUARTERMAN, C.P., GESCHER, A. & SLACK, J.A. (1991). Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-l-yl)imidazole-4-carboxide. Cancer Chemother. Pharmacol., 27, 342.
18. VAN OOSTEROM, A T., STOTER, G., BONO, A.V. & 6 others (1989). Mitozolomide in advanced renal cancer: a phase II study in previously untreated patients from the EORTC Genitourinary Tract Cancer Cooperative Group. Eur. J. Cancer Clin. Oncol., 25, 1249.